| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.883 auroc unitless · higher Uncertainty: 95% CI 0.8672 to 0.8984 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C13; group 'BRCA'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.614 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.5710 to 0.6563 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E13; group 'BRCA'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.524 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.4791 to 0.5689 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D13; group 'BRCA'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.872 auroc unitless · higher Uncertainty: 95% CI 0.8411 to 0.9027 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C23; group 'CHOL'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.71 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.6526 to 0.7674 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E23; group 'CHOL'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.667 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6084 to 0.7249 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D23; group 'CHOL'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.97 auroc unitless · higher Uncertainty: 95% CI 0.9614 to 0.9793 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C33; group 'CRC'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.842 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.7927 to 0.8906 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E33; group 'CRC'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.752 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6928 to 0.8106 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D33; group 'CRC'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Jiang cohort cross-validation, liver cancer (Table S2)
Dataset: Jiang et al. 2018 plasma WGS, 90 liver cancer and 135 non-cancer (as used by Hou et al. 2024) | 0.836 auroc unitless · higher Uncertainty: 95% CI 0.8163 to 0.8547 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Jiang cohort liver cancer cross-validation ctdnafrag-20261009-protocol-hou2024-jiang-lihc-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C83; group 'LIHC'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.915 auroc unitless · higher Uncertainty: 95% CI 0.8718 to 0.9575 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C53; group 'NSCLC'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.84 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.7723 to 0.9077 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E53; group 'NSCLC'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.73 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6475 to 0.8125 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D53; group 'NSCLC'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.855 auroc unitless · higher Uncertainty: 95% CI 0.8310 to 0.8786 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C63; group 'OV'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.563 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.5009 to 0.6258 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E63; group 'OV'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.485 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.4213 to 0.5487 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D63; group 'OV'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.942 auroc unitless · higher Uncertainty: 95% CI 0.9278 to 0.9551 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C73; group 'PAAD'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.808 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.7653 to 0.8513 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E73; group 'PAAD'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.724 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.6751 to 0.7733 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D73; group 'PAAD'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.874 auroc unitless · higher Uncertainty: 95% CI 0.8634 to 0.8848 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C3; group 'PANCAN'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.827 auroc unitless · higher Uncertainty: 95% CI 0.7986 to 0.8552 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, C43; group 'STAD'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.53 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: 95% CI 0.4666 to 0.5934 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, E43; group 'STAD'; row 'length'; column 'Sensitivity @85% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 Cristiano cohort cross-validation, pan-cancer and seven cancer types (Table S2)
Dataset: DELFI 2019 internally cross-validated cancer detection cohort | 0.388 sensitivity-at-95-percent-specificity fraction · higher Uncertainty: 95% CI 0.3241 to 0.4525 Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), Cristiano cohort cross-validation ctdnafrag-20261009-protocol-hou2024-cristiano-cv-sensitivity Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S2, D43; group 'STAD'; row 'length'; column 'Sensitivity @95% specificity' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.664 auroc unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, C13; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'length'; column 'AUC' |
|---|
| Configuration: Fragment length distribution, open chromatin regions, SVM (Hou et al. 2024) | Protocol: Hou et al. 2024 independent validation, Mathios et al. LUCAS cohort (Table S3)
Dataset: Mathios et al. 2021 LUCAS cohort, 129 lung cancer and 158 non-cancer (as used by Hou et al. 2024) | 0.341 sensitivity-at-85-percent-specificity fraction · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible | Independent external evaluation · Source checkedMethods, coverage and sourcelength (open chromatin), independent validation on Mathios et al. LUCAS dataset (LUNG) ctdnafrag-20261009-protocol-hou2024-mathios-lucas-independent Aggregation: Not reported Systematically Evaluating Cell-Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns; Hou et al. 2024, Supporting Information workbook (Tables S1-S15) · Supporting Information sheet S3, E13; data set 'Mathios et al. LUCAS dataset (LUNG)'; row 'length'; column 'Sensitivity @85% specificity' |
|---|